External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma

Cancer

Volumn 119, Issue 10, 2013, Pages 1816-1822

  Iasonos, Alexia ^a   Keung, Emily Z ^b   Zivanovic, Oliver ^c   Mancari, Rosanna ^d   Peiretti, Michele ^d   Nucci, Marisa ^b   George, Suzanne ^b   Colombo, Nicoletta ^e   Carinelli, Silvestro ^d   Hensley, Martee L ^f   Raut, Chandrajit P ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

cancer; International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer; nomogram; staging; uterine leiomyosarcoma; validation

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; DISTANT METASTASIS; FEMALE; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; MITOSIS INDEX; NOMOGRAM; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR VOLUME; UTERUS SARCOMA; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; HYSTERECTOMY; INTERNATIONAL COOPERATION; KAPLAN-MEIER ESTIMATE; LEIOMYOSARCOMA; MIDDLE AGED; MITOTIC INDEX; NEOPLASM GRADING; NEOPLASM STAGING; NOMOGRAMS; PROGNOSIS; SURVIVAL RATE; UTERINE NEOPLASMS;

EID: 84877577148     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27971     Document Type: Article

References (24)

1. Harlow BL, Weiss NS, Lofton S,. The epidemiology of sarcomas of the uterus. J Natl Cancer Inst. 1986; 76: 399-402.
2. Echt G, Jepson J, Steel J, et al. Treatment of uterine sarcomas. Cancer. 1990; 66: 35-39.
3. Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of adjuvant Adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol. 1985; 3: 1240-1245.
4. Reed NS, Mangioni C, Malmstrom H, et al. European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: a European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008; 44: 808-818.
5. Rose PG, Boutselis JG, Sachs L,. Adjuvant therapy for stage I uterine sarcoma. Am J Obstet Gynecol. 1987; 156: 660-662.
6. Sorbe B, Johansson B,. Prophylactic pelvic irradiation as part of primary therapy in uterine sarcomas. Int J Oncol. 2008; 32: 1111-1117.
7. Raut CP, Nucci MR, Wang Q, et al. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. Eur J Cancer. 2009; 45: 2818-2824.
8. Zivanovic O, Leitao MM, Iasonos A, et al. Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer staging systems. J Clin Oncol. 2009; 27: 2066-2072.
9. Prat J,. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet. 2009; 104: 177-178.
10. Iasonos A, Schrag D, Raj GV, et al. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008; 26: 1364-1370.
11. Abu-Rustum NR, Zhou Q, Gomez JD, et al. A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. Gynecol Oncol. 2010; 116: 399-403.
12. Barlin JN, Yu C, Hill EK, et al. Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer. Gynecol Oncol. 2012; 125: 25-30.
13. Zivanovic O, Jacks LM, Iasonos A, et al. A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma. Cancer. 2012; 118: 660-669.
14. Bell SW, Kempson RL, Hendrickson MR,. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol. 1994; 18: 535-558.
15. Gonen M, Heller G,. Concordance probability and discriminatory power in proportional hazards regression. Biometrika. 2005; 92: 965-970.
16. Harrell FE Jr, Lee KL, Mark DB,. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15: 361-387.
17. Sternberg CN,. Are nomograms better than currently available stage groupings for bladder cancer? J Clin Oncol. 2006; 24: 3819-3820.
18. Kattan MW,. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Curr Opin Urol. 2003; 13: 111-116.
19. Weiser MR, Landmann RG, Kattan MW, et al. Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol. 2008; 26: 380-385.
20. Walz J, Gallina A, Saad F, et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol. 2007; 25: 3576-3581.
21. Polterauer S, Zhou Q, Grimm C, et al. External validation of a nomogram predicting overall survival of patients diagnosed with endometrial cancer. Gynecol Oncol. 2012; 125: 526-530.
22. Kondalsamy-Chennakesavan S, Yu C, Kattan MW, et al. Nomograms to predict isolated loco-regional or distant recurrence among women with uterine cancer. Gynecol Oncol. 2012; 125: 520-525.
23. Kattan MW, Leung DH, Brennan MF,. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 2002; 20: 791-796.
24. Swanson GP, Yu C, Kattan MW, et al. Validation of postoperative nomograms in prostate cancer patients with long-term follow-up. Urology. 2011; 78: 105-109.